Net Asset Value as at 31 March 2015

RNS Number : 2025K
Port Erin Biopharma Investments Ltd
15 April 2015
 

15 April 2015

Port Erin Biopharma Investments Limited

(the "Company")

 

Net Asset Value calculation to 31 March 2015

 

Jim Mellon, Chairman, commented: -

"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 March 2015 was 12.32 pence per share, including un-invested cash of £405,665. The portfolio is valued under IFRS at bid price.

Net Assets stand at £2.9 million including Investments of £2.5 million. This follows the successful completion of the tender offer which gave shareholders the opportunity to sell a proportion of their holding back to the Company at their implicit value rather than the historically discounted market price. Our holding in the Magna Biopharma Income Fund now represents 52.2% of the Company's portfolio.

This quarter's NAV represents a decrease of 13.8% from the previous valuation of 14.29 pence per share, which included un-invested cash of £431,744. On this basis, no additional management fee is due to Shellbay Investments Limited.

The reported NAV to 31 March 2015 suffered due to some share price fluctuations in our smaller quoted holdings, all of which have recovered some value in the opening stages of the second quarter. Our principal investment in the Magna Biopharma Income Fund continued to perform strongly, reporting an uplift in share price of 14.7% during the first quarter."



Unaudited to 31 March 2015    £

Fixed Assets




Investments

2,514,425

Current Assets




Sundry Debtors

16,821


Uninvested cash

405,665

Current Liabilities




Creditors: amounts due

(79,678)



2,857,233

Capital and Reserves




Share Capital

23


Share Premium

1,890,142


Current year earnings

(430,980)


Retained earnings

1,398,048



2,857,233




Shares in Issue


23,195,558




Net Asset Value per share


12.32 pence

 

Portfolio Details

 

Investments as at 31 March 2015

Value

% of Total Portfolio






Magna Biopharma Income Fund

£1,312,807

52.2%


Plethora Solutions Holdings

£271,250

10.8%


Summit Corporation

£468,616

18.7%


Other quoted holdings

£116,859

4.6%


Other unquoted holdings

£344,893

13.7%


Total

£2,514,425

100.0%



 

For further information, please contact:

 

Port Erin Biopharma

Investments Limited

Beaumont Cornish Limited

Peterhouse Capital Limited

The Company

Nomad

Broker




Denham Eke

(+44) (0) 1624 639396

Roland Cornish

(+44) (0) 207 628 3396

Lucy Williams

(+44) (0) 207 469 0936

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NAVLLFSSSVISLIE
UK 100

Latest directors dealings